TY - JOUR
T1 - Cross resistance of fluoroquinolone drugs on gyrA gene mutation in Mycobacterium tuberculosis
AU - Park, Young Kil
AU - Park, Chan Hong
AU - Koh, Won Jung
AU - Kwon, O. Jung
AU - Kim, Bum Jun
AU - Kook, Yoon Hoh
AU - Cho, Sang Nae
AU - Chang, Chulhun
AU - Bai, Gill Han
PY - 2005/9
Y1 - 2005/9
N2 - Background: Fluoroquinolone drugs are an important anti-tuberculous agent for the treatment of multi-drug resistant tuberculosis. However, many drugs belonging to the fluoroquinolones have different cross resistance to each other. Methods: Sixty-three ofloxacin (OFX) resistant and 10 pan-susceptible M. tuberculosis isolates were selected, and compared for their cross resistance using a proportion method on Lowenstein-Jensen media, containing ofloxacin (OFX), ciprofloxacin (CIP), levofloxacin (LVX), moxifloxacin (MXF), gatifloxacin (GAT) and sparfloxacin (SPX), at concentrations ranging from 0.5 to 3μg/ml. DNA extracted from the isolates was directly sequenced after amplifying from the gyrA and gyrB genes. Results: The 63 OFX resistant M. tuberculosis isolates showed complete cross resistance to CIP, but only 90.5, 44.4, 36.5 and 46.0% to LVX, MXF, GAT, and to SPX, respectively. Fifty-one of the isolates (81.0%) had point mutations in codons 88, 90, 91 and 94 in gyrA, which are known to be correlated with OFX resistance. The Gly88Ala, Ala90Valand Asp94Ala mutations in gyrA showed a tendency to be susceptible to MXF, GAT and SPX. Only 4 isolates had mutations in the gyrB gene, which did not affect the OFX resistance. Conclusion: About 60% of the OFX resistant M. tuberculosis isolates were, susceptible to GAT, SPX and MXF. These fluoroquinolones may be useful in the treatment of TB patients showing OFX resistance.
AB - Background: Fluoroquinolone drugs are an important anti-tuberculous agent for the treatment of multi-drug resistant tuberculosis. However, many drugs belonging to the fluoroquinolones have different cross resistance to each other. Methods: Sixty-three ofloxacin (OFX) resistant and 10 pan-susceptible M. tuberculosis isolates were selected, and compared for their cross resistance using a proportion method on Lowenstein-Jensen media, containing ofloxacin (OFX), ciprofloxacin (CIP), levofloxacin (LVX), moxifloxacin (MXF), gatifloxacin (GAT) and sparfloxacin (SPX), at concentrations ranging from 0.5 to 3μg/ml. DNA extracted from the isolates was directly sequenced after amplifying from the gyrA and gyrB genes. Results: The 63 OFX resistant M. tuberculosis isolates showed complete cross resistance to CIP, but only 90.5, 44.4, 36.5 and 46.0% to LVX, MXF, GAT, and to SPX, respectively. Fifty-one of the isolates (81.0%) had point mutations in codons 88, 90, 91 and 94 in gyrA, which are known to be correlated with OFX resistance. The Gly88Ala, Ala90Valand Asp94Ala mutations in gyrA showed a tendency to be susceptible to MXF, GAT and SPX. Only 4 isolates had mutations in the gyrB gene, which did not affect the OFX resistance. Conclusion: About 60% of the OFX resistant M. tuberculosis isolates were, susceptible to GAT, SPX and MXF. These fluoroquinolones may be useful in the treatment of TB patients showing OFX resistance.
UR - http://www.scopus.com/inward/record.url?scp=26944439477&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=26944439477&partnerID=8YFLogxK
U2 - 10.4046/trd.2005.59.3.250
DO - 10.4046/trd.2005.59.3.250
M3 - Article
AN - SCOPUS:26944439477
SN - 1738-3536
VL - 59
SP - 250
EP - 256
JO - Tuberculosis and Respiratory Diseases
JF - Tuberculosis and Respiratory Diseases
IS - 3
ER -
